AI for science · Company
Insilico Medicine is a clinical-stage biotechnology company building an end-to-end generative AI platform for drug discovery and clinical development (marketed as Pharma.AI). The company combines AI-based target identification and molecular generation with clinical trial outcome prediction and tightly couples these in-silico steps to automated laboratory workflows via its Life Star robotics lab(s).
In parallel to internal pipeline development, Insilico commercializes its platform through software licensing and out-licensing/co-development agreements with pharma partners, which it describes as a revenue stream alongside advancing its own drug candidates. Strategically, Insilico has shifted from venture-backed private-company execution into a public-company growth phase after listing on the Main Board of the Hong Kong Stock Exchange under stock code 03696.HK (listed on 2025-12-30). Its more recent (2026) announcements emphasize expanding partnerships that apply Pharma.AI across therapeutic areas (for example Takeda), and advancing clinical programs toward late-stage development, including Phase III initiation for its TNIK inhibitor Rentosertib (IPF).
| Headline | Source | Date |
|---|---|---|
| Insilico Medicine Announces ARDD 2026 Program (Aging Research & Drug Discovery)Insilico announced the program for ARDD 2026, scheduled for October 1–3, 2026 at Harvard University; the company also stated the program is anchored by Insilico and Eli Lilly. | ||
| Insilico Medicine Demonstrates AI-Powered Target Discovery for Rare Sinonasal Cancer (npj Precision Oncology)Insilico announced publication of a collaborative study in npj Precision Oncology describing a multi-omic AI approach for rare sinonasal cancer target discovery and generation of actionable therapeutic hypotheses. | ||
| Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331Insilico reported that first-in-human Phase 1 data for ISM6331 (a novel AI-designed pan-TEAD inhibitor) was accepted for Rapid Oral presentation at ESMO 2026 (Oct 23–27, 2026). | ||
| Insilico Initiates Phase III Clinical Trial for Rentosertib (TNIK inhibitor) for Idiopathic Pulmonary Fibrosis |
| Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug DiscoveryInsilico announced a strategic collaboration agreement with Takeda to use Insilico’s Pharma.AI platform for discovery and clinical-validation support across Takeda therapeutic areas; Insilico stated it would lead AI-driv… |
| Insilico Medicine Announces Industry’s First Longevity Board to Accelerate AI-Driven Aging Research for Drug DiscoveryInsilico announced formation of an industry longevity board intended to accelerate AI-driven aging research for drug discovery, positioned as connected to its GLP-1 and longevity discussion themes. |
| Insilico Medicine Advances AI-Driven Target Discovery with Validated TargetPro–TargetBench FrameworkInsilico announced updates integrating its Target Identification Pro and Target Identification Benchmark into a validated framework intended to improve accuracy, reliability, and scalability for early-stage drug target d… |
| Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women’s HealthInsilico and ASKA Pharmaceutical announced an expanded collaboration aimed at discovering novel targets for women’s health. |